Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets

Robert J. Herman
University of Calgary
herman@ucalgary.ca
Conflict of Interest Disclosure

None
Learning Objectives

1. Understand the pharmacology of common classes of blood pressure lowering medications and how to use them more effectively

2. Recognize isolated systolic hypertension as a unique entity with specific issues in the elderly and cardiac patients and know which drugs work best/less well

3. Understand the issues surrounding resistant hypertension and recognize common causes before ordering expensive tests and procedures to rule out rare conditions
CASE: Newly Diagnosed Hypertensive

• 42 yr male is referred for BP of 150/95 mmHg
  – Positive family Hx for HTN and premature CAD
  – No clinical evidence of target organ injury
  – Routine testing is normal; A1C and LDL are also normal

  Advise: HBPM measurements twice/d for 2 wks

• F/U in 2 wks, office and home measurements; BP still 150/95 in office, 145/90 at home

  Advise: Start ramipril 5mg/d

• Returns 2 wks later with office BP 150/95
How long to see the full anti-hypertensive effect of monotherapy with a BP-lowering medication?

• 4-6 wks for most agents, 2 wks for combination products


• More rapidly-acting drugs for use in HE/HU

**Intravenous**
- Nitroprusside 0.5 - 10 μg/kg/min continuous IV infusion
- Labetalol 20 mg IV every 10 min to a total of 300 mg
- Hydralazine 10 - 20 mg IV every 4 - 6 hours

**Oral**
- Clonidine 0.2 mg loading, 0.1 mg bid to follow
- Labetalol 100-300 mg bid
- Adalat XL 60 mg
How long to see the full anti-hypertensive effect of monotherapy with a BP-lowering medication?

- 4-6 wks for most agents, 2 wks for combination products

- More rapidly-acting drugs for use in HE/HU

  Intravenous
  Nitroprusside 0.5 - 10 μg/kg/min continuous IV infusion
  Labetalol 20 mg IV every 10 min to a total of 300 mg
  Hydralazine 10 - 20 mg IV every 4 - 6 hours

  Oral
  Clonidine 0.2 mg loading, 0.1 mg bid to follow
  Labetalol 100-300 mg bid
  Adalat XL 60 mg

NOTE: ACEi are on neither of these lists WHY???
Is it better to change to another anti-hypertensive drug class, increase the dose or add a second agent?

• Many anti-hypertensive agents have flat dose response curves
  – Thiazide Diuretics
  – ACEi/ARBs


• Several RCTs examining doubling the dose versus adding a second agent show clear superiority for adding on another treatment
Don’t Combine Agents Having the Same Mechanism of Action

RAAS Blockers

Don’t combine an ARB with an ACEi

Vasodilators

Don’t combine hydralazine with a CCB

Diuretics

Do combine thiazides & potassium-sparing diuretics

Anti-adrenergics

Do combine alpha & beta-blockers

Do combine central & peripherally-acting sympatholytics
Other Pearls

A diuretic should be part of every multi-drug anti-hypertensive regimen

Beta-blockers are effective renin inhibitors
   In addition to 1st line, use as 3rd or 4th line instead of more expensive direct renin inhibitors (aliskiren)

Alpha-1 blockers have adverse outcome data

Nitrates do not dilate arteries and are not effective BP-lowering medication unless levels are 20x usual [nitrate] (used intra-arterially)
What is the recommended treatment target for this particular patient?

- Office < 140/90 and/or home < 135/85 mmHg
- Office <130/80 mmHg
- Office sBP < 120 mmHg
# 2018 Hypertension Canada Guidelines

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>BP (mmHg) Threshold to Initiate Drug Rx*</th>
<th>BP (mmHg) Target*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk (No TOD or CVRF)</td>
<td>sBP ≥ 160 (Grade A) dBP ≥ 100 (Grade A)</td>
<td>sBP &lt; 140 (Grade A) dBP &lt; 90 (Grade A)</td>
</tr>
<tr>
<td>High-risk</td>
<td>sBP ≥ 130 (Grade B)</td>
<td>sBP &lt; 120 (Grade B)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>sBP ≥ 130 (Grade C) dBP ≥ 80 (Grade A)</td>
<td>sBP &lt; 130 (Grade C) dBP &lt; 80 (Grade A)</td>
</tr>
<tr>
<td>All others</td>
<td>sBP ≥ 140 (Grade C) dBP ≥ 90 (Grade A)</td>
<td>sBP &lt; 140 (Grade A) dBP &lt; 90 (Grade A)</td>
</tr>
</tbody>
</table>

* If using HBP or daytime ABPM, subtract 5 mmHg
High-risk Adult Candidates for Aggressive BP Lowering

1. Clinical or subclinical cardiovascular disease, or ...

2. CKD (non diabetic, proteinuria < 1 gm/d, GFR (MDRD) 20-59 ml/min/1.73m²), or ...

3. Estimated Framingham 10-yr global risk ≥ 15%, or ...

4. Age ≥ 75 yrs
CASE: Ms. Elderly Hypertensive

74 yr. old female
HTN for 10 yrs, BP labile 150-210/60-90
Many meds; ineffective or with adverse effects;
    now on Bisoprolol 5 mg od
No history or symptoms of prior CV disease
Non smoker, no EtOH
No family history of HTN or CVD

EXAMINATION

HR 50 bpm  BP 160/70 supine, 100/55 upright
    with orthostatic  Sx
Isolated Systolic Hypertension is due to thickening and hardening of the large conduit arteries
Windkessel Effect

Impedence point

Windkessel Effect
MAP = CO \times TPR

***Variability is the hallmark of ISH
MAP = CO x TPR

***Variability is the hallmark of ISH
Stiff arteries may lead to systematic error (increases) in the measurement of BP

Pseudohypertension
TREATING ISH

• Start with a diuretic or a long-acting dihydropyridine calcium channel blocker
• Use low dosages and increase slowly
• Avoid beta blockers, unless indicated for other reasons, as these may worsen BP control
• Other drugs can work if used in combination
• Watch for orthostatic hypotension. The mortality and morbidity from falls in the elderly may be greater than the benefit derived from BP lowering
CASE: Difficult to Control Hypertension

53 yr male admitted HTN Emergency Feb 2008
BMI 28.8, BP 214/185mmHg, grade III retina
Follows a low Na\(^+\) diet, minimal EtOH
No OTC meds of interest
OSA on nightly CPAP
Echo LVH, K\(^+\) chronically 3.1
1.3x1.2 mass (L) adrenal, 24Hr urine for metanephrine N x 2
MRA kidneys normal
Aldo 552pM/L, Renin 0.46mg/L/sec, ARR 1200 (N)
24Hr urinary cortisol & AM cortisol (N)

Stabilized on HCTZ 25/Adalat XL 30/Lisinopril 20 bid

Feb’10 BP 132/82; is now diabetic/nephropathy. GP has started metformin 500 tid + repaglinide 2 tid

Jun’11 BP 153/93 ???

What is the issue here?
Definition:

Blood pressure that remains above goal in spite of the concurrent use of 3 antihypertensive agents of different classes. Ideally, 1 should be a diuretic and all agents should be prescribed at optimal doses.

AHA Scientific Statement. Hypertension 2008;51:1403-1419
Resistant Hypertension

Pseudo-Resistant HTN
- Error in BP Measurement
  - Improper cuff size
  - Improper measurement technique
- Whitecoat Hypertension
- Non Adherence / Non Compliance
  - Patient factors
  - Physician factors
- Drugs that ↑ BP or interfere with BP-lowering medication

True Resistant HTN
Decrease in adherence due to discontinuation of treatment (nonpersistence)

% of patients engaged with the dosing regimen

% of patients who dosed correctly

True Resistant Hypertension

Secondary HTN
- OSA
- Renal vascular or parenchymal disease
- Metabolic Syndrome
- Hypo/Hyperthyroidism
- Primary Aldosteronism

Rare endocrine disease
Other uncommon causes
Start with Lifestyle Interventions

Limit Sodium intake to < 2000 mg/d (5 gm salt)
Exercise 40 min/d 5 days out of 7
Weight control
Smoking cessation (2 yrs to risk of a non smoker)
Limit EtOH consumption
Optimize Diuretic Treatment by Switching to a Long-acting Thiazide

Chlorthalidone PK properties:
longer t1/2, 3-fold greater potency/duration of action

Clinical trials:
HDFP, ALLHAT, SHEP all used chlorthalidone; multiple studies of HCTZ, but only in combination products

Head-to-head comparison of chlorthalidone vs HCTZ:
ABPM greater 24 hour BP lowering effect at night
No comparison of cardiovascular outcomes in the literature
Ernst ME et al. Hypertension 2006;47:352-8
2012 Cochrane Review:
- five crossover RCTs
- mean BP decreases of 20/7 mmHg
- no DRAE at Spironolactone doses below 100 mg/day
- no data on clinical outcomes
2012 Cochrane Review - five crossover RCTs
- mean BP decreases of 20/7 mmHg
- no DRAE at Spironolactone doses below 100 mg/day
- no data on clinical outcomes

Chaplin et al. Hypertension 2007; 49: 839-845

If testing for PA is a consideration, do your testing before starting Spironolactone.
Lower on the List, in Combination Rx

Increase the dose of the CEB Clonidine

Low dose, 0.1 mg bid

Beta-blockers

These are renin blockers
Labetalol has added $\alpha_1$-blockade

Alpha blockade

Doxazosin: Caveat - withdrawn from ALLHAT because of adverse outcomes

Adapted from Resistant Hypertension, presented by K. Zarnky
Rocky Mountain/ACP Internal Medicine Meeting 2011
Summary: Investigation & Treatment RHTN

1. Confirm the BP measurement
2. Evaluate non-adherence
3. Identify interfering meds/other agents causing HTN
4. Screen for secondary causes (esp CKD, Metabolic Syndrome, HoThy, OSA, PA)
5. Address lifestyle issues
6. Optimize antihypertensive therapy
   - Add or switch to chlorthalidone 12.5 mg/d
   - Add spironolactone 12.5-25 mg/d
7. Follow, follow & follow up, again ... consider Testing
Our Patient with resistant HTN, continued ...

- Jun’11 BP 153/93; Creat 129; started spironolactone 25 ➔ 12.5 mg b/o breast effects
- Oct’12 BP 145/90; switch HCTZ ➔ chlorthalidone 12.5 mg/d
- Jan’ 13 BP 122/84; Creat 218
- Jan’ 18 gets an itchy red rash?
My Last Pearl ...

Ethacrinic acid is loop diuretic that is not a sulphonamide-derivative
Discussion and Questions